• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Scopus
  4. Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations
 
  • Details
  • Full
Options
2025
Journal Article
Title

Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations

Abstract
Constitutive JAK/STAT pathway activation is crucial in the pathogenesis of BCR::ABL1-negative myeloproliferative neoplasms (MPN), but has not yet been linked to interferon (IFN)-γ signaling and tumor microenvironment. Human JAK2 V617F-mutated cell lines, 265 bone marrow biopsies (BMB) of two MPN cohorts, and 50 non-neoplastic BMB, revealed an intrinsic activation of IFN-γ signaling, which was confirmed by public RNA expression data. In vitro analysis of JAK2-mutated cell lines showed an activation of IFN-γ signaling pathway in the absence of IFN-γ in the cell supernatants. In addition, a heterogeneous, but increased expression of IFN-γ signaling components was found in BMB of JAK2-mutated samples with the highest expression in lymphocytes and monocytes, accompanied by increased tumor infiltrating lymphocytes (TIL). Unsupervised clustering identified a prognostic favorable cluster in both patient cohorts characterized by augmented IFN-γ signaling and TILs. This cluster was enriched with JAK2-mutated, JAK-inhibition naive MPN, mainly essential thrombocythemia and polycythemia vera with mild bone marrow fibrosis. Moreover, in silico data confirmed the link between JAK2 mutations and increased IFN-γ signaling. Multivariate Cox regression revealed TILs to be the strongest prognostic marker. In conclusion, JAK2-mutated MPN exhibit an intrinsic activation of IFN-γ signaling associated with changes in the BM TME and patients’ outcome. (Figure presented.)
Author(s)
Bauer, Marcus
Universitätsklinikum Halle und Medizinische Fakultät
Vaxevanis, Christoforos K.
Universitätsklinikum Halle und Medizinische Fakultät
Jaekel, Nadja
Universitätsklinikum Halle und Medizinische Fakultät
Hackl, Hubert
Medizinische Universitat Innsbruck
Wilfer, Andreas
Universitätsklinikum Halle und Medizinische Fakultät
Zoellig, Clara
Martin Luther University Halle-Wittenberg
Haemmerle, Monika
Universitätsklinikum Halle und Medizinische Fakultät
Müller-Tidow, Carsten
Universitätsklinikum Heidelberg
Al-Ali, Haifa Kathrin
Universitätsklinikum Halle und Medizinische Fakultät
Seliger, Barbara
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Wickenhauser, Claudia
Universitätsklinikum Halle und Medizinische Fakultät
Journal
Leukemia  
Open Access
DOI
10.1038/s41375-025-02706-3
Additional link
Full text
Language
English
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024